IL104351A - Rifabutin for use in preventing or delaying onset of mycobacterial infections in immunocompromised patients - Google Patents

Rifabutin for use in preventing or delaying onset of mycobacterial infections in immunocompromised patients

Info

Publication number: IL104351A
Authority: IL; Israel
Prior art keywords: mycobacterium; rifabutin; use according; mycobacterial; patient
Prior art date: 1992-01-13

Application number

IL104351A

Other languages

English (en)

Other versions

IL104351A0 (en

Inventor

Phillip L Banks

Beverley A Wynne

Richard L Wolgemuth

Original Assignee

Erbamont Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-13

Filing date

1993-01-08

Publication date

1998-03-10

1993-01-08 Application filed by Erbamont Inc filed Critical Erbamont Inc

1993-05-13 Publication of IL104351A0 publication Critical patent/IL104351A0/xx

1998-03-10 Publication of IL104351A publication Critical patent/IL104351A/en

Links

ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 title claims description 43
229960000885 rifabutin Drugs 0.000 title claims description 42
206010061598 Immunodeficiency Diseases 0.000 title claims description 23
208000027531 mycobacterial infectious disease Diseases 0.000 title claims description 21
206010062207 Mycobacterial infection Diseases 0.000 title claims description 18
208000030507 AIDS Diseases 0.000 claims description 29
241001502334 Mycobacterium avium complex bacterium Species 0.000 claims description 18
239000003814 drug Substances 0.000 claims description 7
241000513886 Mycobacterium avium complex (MAC) Species 0.000 claims description 5
241000187479 Mycobacterium tuberculosis Species 0.000 claims description 5
241000186359 Mycobacterium Species 0.000 claims description 3
241000186363 Mycobacterium kansasii Species 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
241000186365 Mycobacterium fortuitum Species 0.000 claims description 2
241000187492 Mycobacterium marinum Species 0.000 claims description 2
241000187481 Mycobacterium phlei Species 0.000 claims description 2
241000187917 Mycobacterium ulcerans Species 0.000 claims description 2
241000187494 Mycobacterium xenopi Species 0.000 claims description 2
229940055036 mycobacterium phlei Drugs 0.000 claims description 2
241001058146 Erium Species 0.000 claims 1
241000894007 species Species 0.000 claims 1
208000015181 infectious disease Diseases 0.000 description 21
238000000034 method Methods 0.000 description 11
201000008827 tuberculosis Diseases 0.000 description 10
229940068196 placebo Drugs 0.000 description 9
239000000902 placebo Substances 0.000 description 9
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
239000002775 capsule Substances 0.000 description 5
208000001388 Opportunistic Infections Diseases 0.000 description 4
238000009640 blood culture Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229940079593 drug Drugs 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000011282 treatment Methods 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
206010038705 Respiratory moniliasis Diseases 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
206010003754 Atypical mycobacterial infections Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
206010024229 Leprosy Diseases 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
-1 N-isobutyl-4-piperidyl Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000001355 anti-mycobacterial effect Effects 0.000 description 2
239000003926 antimycobacterial agent Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000022155 mycobacterium avium complex disease Diseases 0.000 description 2
229960001225 rifampicin Drugs 0.000 description 2
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
239000002689 soil Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
ZYECOAILUNWEAL-NUDFZHEQSA-N (4z)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-n-(3-nitrophenyl)-3-oxonaphthalene-2-carboxamide Chemical compound COC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1N\N=C(C1=CC=CC=C1C=1)/C(=O)C=1C(=O)NC1=CC=CC([N+]([O-])=O)=C1 ZYECOAILUNWEAL-NUDFZHEQSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
241000203809 Actinomycetales Species 0.000 description 1
241000427202 Adria Species 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
208000008953 Cryptosporidiosis Diseases 0.000 description 1
206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000002971 Immunoblastic Lymphadenopathy Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000186360 Mycobacteriaceae Species 0.000 description 1
206010058806 Mycobacterium avium complex infection Diseases 0.000 description 1
241000187484 Mycobacterium gordonae Species 0.000 description 1
241001147828 Mycobacterium haemophilum Species 0.000 description 1
241000186362 Mycobacterium leprae Species 0.000 description 1
241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
241000187480 Mycobacterium smegmatis Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010030154 Oesophageal candidiasis Diseases 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000233870 Pneumocystis Species 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
229930189077 Rifamycin Natural products 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
XJGUKDJAOUXADK-UHFFFAOYSA-N [difluoro(naphthalen-2-yl)methyl]phosphonic acid Chemical compound C1=CC=CC2=CC(C(F)(F)P(O)(=O)O)=CC=C21 XJGUKDJAOUXADK-UHFFFAOYSA-N 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
229960004287 clofazimine Drugs 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
201000005655 esophageal candidiasis Diseases 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
208000033065 inborn errors of immunity Diseases 0.000 description 1
239000000411 inducer Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000009533 lab test Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
206010029410 night sweats Diseases 0.000 description 1
230000036565 night sweats Effects 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000028529 primary immunodeficiency disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
229940081192 rifamycins Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL104351A 1992-01-13 1993-01-08 Rifabutin for use in preventing or delaying onset of mycobacterial infections in immunocompromised patients IL104351A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US82010892A	1992-01-13	1992-01-13

Publications (2)

Publication Number	Publication Date
IL104351A0 IL104351A0 (en)	1993-05-13
IL104351A true IL104351A (en)	1998-03-10

Family

ID=25229906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL104351A IL104351A (en)	1992-01-13	1993-01-08	Rifabutin for use in preventing or delaying onset of mycobacterial infections in immunocompromised patients

Country Status (8)

Country	Link
EP (1)	EP0552018A1 (fr)
JP (1)	JPH06508852A (fr)
AU (2)	AU2451792A (fr)
CA (1)	CA2080040C (fr)
IL (1)	IL104351A (fr)
NZ (1)	NZ244322A (fr)
WO (1)	WO1993013774A1 (fr)
ZA (1)	ZA93197B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2320337C1 (ru) *	2006-06-09	2008-03-27	Федеральное государственное унитарное предприятие "Государственный научный центр по антибиотикам"	Способ получения антимикробной композиции с рифабутином
WO2017013239A1 (fr) *	2015-07-22	2017-01-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Activateurs de nrf2 pour le traitement d'infections mycobactériennes

1992
- 1992-09-14 NZ NZ244322A patent/NZ244322A/en unknown
- 1992-09-16 AU AU24517/92A patent/AU2451792A/en not_active Abandoned
- 1992-10-07 CA CA002080040A patent/CA2080040C/fr not_active Expired - Fee Related
1993
- 1993-01-08 IL IL104351A patent/IL104351A/en not_active IP Right Cessation
- 1993-01-11 JP JP5512662A patent/JPH06508852A/ja active Pending
- 1993-01-11 WO PCT/US1993/000335 patent/WO1993013774A1/fr not_active Ceased
- 1993-01-12 ZA ZA93197A patent/ZA93197B/xx unknown
- 1993-01-13 EP EP93300187A patent/EP0552018A1/fr not_active Withdrawn
1995
- 1995-12-15 AU AU40434/95A patent/AU4043495A/en not_active Abandoned

Also Published As

Publication number	Publication date
IL104351A0 (en)	1993-05-13
JPH06508852A (ja)	1994-10-06
WO1993013774A1 (fr)	1993-07-22
NZ244322A (en)	1997-07-27
CA2080040C (fr)	1997-03-25
ZA93197B (en)	1993-08-13
AU2451792A (en)	1993-07-15
EP0552018A1 (fr)	1993-07-21
CA2080040A1 (fr)	1993-07-14
AU4043495A (en)	1996-02-22

Legal Events

Date	Code	Title	Description
1998-09-24	FF	Patent granted
1999-12-31	RH	Patent void

Publication	Publication Date	Title
US5997912A (en)	1999-12-07	Method for inhibiting growth of P. aeruginosa using gallium-containing compounds
Ji et al.	1993	Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice
Ji et al.	1995	In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis
Heifets et al.	1990	Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.
Truffot-Pernot et al.	1991	Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments
Botha et al.	1996	Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis
Lounis et al.	1997	Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?
Truffot-Pernot et al.	1995	Clarithromycin is inactive against Mycobacterium tuberculosis
WO2015107482A1 (fr)	2015-07-23	Association pharmaceutique pour traiter la tuberculose
Lounis et al.	2004	In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections
Young	1993	Mycobacterial diseases and the compromised host
WO2022046594A1 (fr)	2022-03-03	Traitement de maladies infectieuses à l'aide d'inhibiteurs de protéine de la famille bcl-2
Fergie et al.	1997	Intrathoracic Mycobacterium avium complex infection in immunocompetent children: case report and review
Valero et al.	1994	Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection
Davies	1994	Tuberculosis in the elderly
IL104351A (en)	1998-03-10	Rifabutin for use in preventing or delaying onset of mycobacterial infections in immunocompromised patients
Yamamoto et al.	1996	In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis
US6399607B1 (en)	2002-06-04	Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin
Kaur et al.	2001	In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria
Burns et al.	1974	Infections of the lower respiratory tract: treatment with amoxicillin
CN119564683B (zh)	2025-09-12	一种抗分枝杆菌感染的联合增效药物组合物
CN102138917A (zh)	2011-08-03	二甲基黄青霉素在制备抗结核药物中的应用
KR101401869B1 (ko)	2014-05-30	에스트로젠의 마이코박테리아 균주 감염 억제용 용도
KR102659126B1 (ko)	2024-04-19	항결핵 약학조성물
AU3364293A (en)	1993-09-01	The use of a compound for the manufacture of a medicament for the treatment of HIV infection